Boxer Capital SC 13D/AOdonate Therapeutics / Boxer Capital ownership change

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13D

(Rule 13d-101)

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

Odonate Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.01 par value

(Title of Class of Securities)

676079106

(CUSIP Number)

David A. Brown

Alston & Bird LLP

950 F Street, N.W.

Washington, DC 20004-1404

202-239-3463

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

November 17, 2021

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  ☐.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

This Amendment No. 3 (“Amendment No. 3”) amends and supplements the statement on Schedule 13D filed on December 8, 2017 (the “Original Filing”) by Boxer Capital, LLC (“Boxer Capital”), Boxer Asset Management (“Boxer Management”), Aaron I. Davis, and Joe Lewis (together with Boxer Capital, Boxer Management and Mr. Davis, the “Reporting Persons”), as amended by Amendment No. 1, filed by the Reporting Persons on December 27, 2018 and Amendment No. 2, filed by the Reporting Persons on September 1, 2020. The Original Filing, as amended, remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment No. 3. Capitalized terms used and not defined in this Amendment No. 3 have the meanings set forth in the Original Filing, as amended.

Item 5 is hereby amended and restated in its entirety as follows:

(a) The Reporting Persons may be deemed to beneficially own, in the aggregate, 5,052,842 shares of Common Stock, representing 13.1% of the Issuer’s outstanding Common Stock. Boxer Capital, Boxer Management and Joe Lewis beneficially own 4,607,086 shares of Common Stock, which represents 12.0% of the Issuer’s outstanding Common Stock. Aaron I. Davis beneficially owns 445,756 shares of Common Stock, which represents 1.2% of the Issuer’s outstanding Common Stock. All percentages are based on 38,490,336 shares of the Issuer’s Common Stock outstanding as of October 29, 2021 as set forth in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021.

(b) With respect to any rights or powers to vote, or to direct the vote of, or to dispose of, or direct the disposition of, the Common Stock owned by the Reporting Persons:

(i) Sole power to vote or direct the vote:

Aaron I. Davis has the sole power to vote or to direct the vote of the 445,756 shares of Common Stock he beneficially owns.    

(ii) Shared power to vote or to direct the vote:

Boxer Capital, Boxer Management and Joe Lewis have shared power to vote or to direct the vote of the 4,607,086 shares of Common Stock they beneficially own.

(iii) Sole power to dispose or to direct the disposition of:

Aaron I. Davis has the sole power to dispose or to direct the disposition of the 445,756 shares of Common Stock he beneficially owns.

(iv) Shared power to dispose or to direct the disposition of:

Boxer Capital, Boxer Management and Joe Lewis have shared power to dispose or to direct the disposition of the 4,607,086 shares of Common Stock they beneficially own.

(c) Other than as set forth below, the Reporting Persons have not engaged in any transactions in the Common Stock in the past 60 days.

(i) Aaron I. Davis effected the following transactions in the Common Stock in the last 60 days:

(ii) Boxer Capital effected the following transactions in the Common Stock in the last 60 days.

(d) No other person has the right to receive or the power to direct the receipt of dividends, or proceeds of sale of such securities outlined in this report.

(e) Not applicable.

Item 7. Material to Be Filed as Exhibits.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 22, 2021